Appendix 4: Supplementary forest plots [posted as supplied by author]


Ampicillin resistance in *E. coli* urinary isolates from children, by OECD status

country	Number of studies	Number of isolates tested			ES (95% CI)
OECD Ireland USA* Greece Turkey* Italy Switzerland UK* Belgium* Israel* Austria* Australia Subtotal (I-se	1 6 3 5 1 3 3 1 1 1 1 1 quared = 6.6	13034 46699 862 4484 177 454 3557 189 160 478 90 5%, p = 0.356)		* * * * * * * *	0.66 (0.65, 0.66) 0.46 (0.43, 0.48) 0.51 (0.47, 0.55) 0.69 (0.63, 0.74) 0.51 (0.44, 0.59) 0.41 (0.30, 0.53) 0.41 (0.33, 0.50) 0.58 (0.51, 0.65) 0.47 (0.39, 0.55) 0.59 (0.54, 0.63) 0.54 (0.44, 0.64) 0.53 (0.46, 0.60)
Non-OECD Saudi-Arabia Jordan Iran Brazil* Taiwan Oman Kuwait* Tanzania* Nigeria* Ghana* Nepal	* 2 2 3 1 1 1 1 1 1	771 766 282 206 136 120 67 25 17 15 12 5%, p = 0.183)		* * * * * * * * * * * * * * * * * * *	0.76 (0.73, 0.79) 0.83 (0.80, 0.85) 0.82 (0.77, 0.86) 0.46 (0.39, 0.52) 0.75 (0.67, 0.82) 0.63 (0.54, 0.71) 0.75 (0.63, 0.84) 0.96 (0.80, 0.99) 1.00 (0.82, 1.00) 1.00 (0.80, 1.00) 0.92 (0.65, 0.99) 0.80 (0.73, 0.88)
•			0 .2 .	1	

ES = Effect size

^{*}Indicates antibiotic is first-line treatment choice

Co-amoxiclav resistance in *E. coli* urinary isolates from children, by OECD status



ES = Effect size

^{*}Indicates antibiotic is first-line treatment choice

Co-trimoxazole resistance in *E. coli* urinary isolates from children, by OECD status

	Numbero	Number of of isolates		
country	studies	tested		ES (95% CI)
OECD				
Greece*	3	862		0.27 (0.19, 0.37
Austria*	1	478	*	0.29 (0.25, 0.34
USA*	7	46836		0.20 (0.18, 0.22
Belgium*	1	189	-	0.36 (0.29, 0.43
Italy*	1	177	*	0.18 (0.13, 0.24
Israel*	1	160	-	0.36 (0.29, 0.44
Switzerland*	3	454		0.20 (0.15, 0.27
Chile	1	100		0.34 (0.25, 0.44
Turkey*	6	4655	•	0.53 (0.49, 0.57
Subtotal (I-squar	red = 28.1%,	p = 0.590)		0.30 (0.21, 0.39
	,	,		•
Non-OECD				
Jordan*	2	797		0.72 (0.68, 0.75
Nepal	2	317	4	 0.77 (0.72, 0.82
United Arab Emir	ates1	208	-	0.62 (0.55, 0.68
Saudi-Arabia*	1	175	-	0.56 (0.49, 0.63
Taiwan	1	136	-	0.29 (0.22, 0.37
Iran*	6	609	-	- 0.72 (0.64, 0.80
Brazil*	2	433		0.44 (0.28, 0.60
Tanzania*	1	25		1.00 (0.87, 1.00
Nigeria*	1	17		1.00 (0.82, 1.00
Ghana*	1	15	_	· 0.87 (0.62, 0.96
Subtotal (I-squar	red = 36.6%,	p = 0.219)		> 0.70 (0.58, 0.82
			0 .2 .4 .6 .	8 1

ES = Effect size
Ordered by increasing standard error
*Indicates antibiotic is first-line treatment choice


Trimethoprim resistance in *E. coli* urinary isolates from children, by OECD status

country	Number of studies	Number of isolates tested			ES (95% CI)
OECD					
Ireland*	1	13034		•	0.32 (0.31, 0.33)
Sweden*	1	928	•		0.14 (0.12, 0.17)
UK*	3	5375	•	•	0.25 (0.21, 0.29)
Austria*	1	478		•	0.29 (0.25, 0.34)
Australia*	1	90	-	-	0.16 (0.09, 0.24)
Subtotal (I-sq	uared = 15.8	%, p =0.310)	<	>	0.23 (0.14, 0.32)
Non-OECD					
Saudi-Arabia	1	596		•	0.68 (0.64, 0.72)
			0 .2 .4 .6 .8 1		
			Proportion of resistant isolates		

ES = Effect size

^{*}Indicates antibiotic is first-line treatment choice


Nitrofurantoin resistance in *E. coli* urinary isolates from children, by OECD status



ES = Effect size

^{*}Indicates antibiotic is first-line treatment choice


Ciprofloxacin resistance in *E. coli* urinary isolates from children, by OECD status



ES = Effect size

^{*}Indicates antibiotic is first-line treatment choice

Ceftazidime resistance in *E. coli* urinary isolates from children, by OECD status



ES = Effect size

^{*}Indicates antibiotic is first-line treatment choice